Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...

A second drug candidate, BBO-10203, blocks the interaction between RAS and PI3K alpha, a family of enzymes involved in cellular growth and proliferation. While PI3K alpha inhibitors have reached ...

The Scorpion drug, STX-478, is a small molecule designed to selectively block PI3K alpha. Overactivation of this enzyme can help cancer grow and spread. While there are drugs available that ...

The PIK3CA gene, which encodes the p110α subunit of phosphoinositide 3-kinase (PI3K), is among the most frequently mutated oncogenes in cancer. These mutations drive tumor progression ...

OnKure's drug candidate pipeline is highlighted by OKI-219, a selective PI3K alpha H1047R inhibitor for the treatment of certain types of breast cancer that began clinical trials in February 2024.

Despite these differences, the authors found that chemotaxis and electrotaxis share a dependence on similar intracellular signaling molecules, most notably the phosphoinositide 3-kinase (PI3K ...